Bladder Cancer Weekly

April 20, 2026

Videos

Peer-to-Peer Clinical Conversations

BRAVO Study Examines Cost and Recurrence Outcomes of Blue Light Cystoscopy in NMIBC - Stephen Williams

Stephen Williams

Ashish Kamat speaks with Stephen Williams about the BRAVO study, a propensity-matched retrospective analysis of 311 blue light versus 311 white light cystoscopy patients with NMIBC in the VA Healthcare System from 1997 to 2021.

View

Optimizing TURBT: Balancing Surgical Skill and Advanced Technology - Mark Tyson & Vignesh Packiam

Vignesh Packiam

Ashish Kamat is joined by Vignesh Packiam and Mark Tyson for a mini-debate on optimal TURBT techniques.

View

Beyond the Abstracts

Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer - Beyond the Abstract

T Cell Subsets of Urine-Derived Lymphocytes (UDLs) Serve as an Indicator of TILs and Reflect Immunological Sex Differences in Bladder Cancer - Beyond the Abstract

Conference Coverage

SES AUA 2026: Application of Machine Learning Models for Predicting Postoperative Ileus after Radical Cystectomy

SES AUA 2026: Implementation of Patient Reported Outcomes as a NMIBC Clinical Trial Endpoint

EAU 2026: Nectin4-Targeted Fluorescence Imaging for Enhanced TURBT: From Preclinical Validation to First in Human Application

EAU 2026: Trial Design Drives Outcomes: Harmonizing Efficacy Across BCG-Unresponsive Bladder Carcinoma in Situ Trials

ASCO GU 2026: FOR: Bacillus Calmette-Guérin Plus Immune Checkpoint Inhibition for High-Risk Non-Muscle-Invasive Bladder Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer.

Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French association of Urology for the management of adverse events and complications of BCG.

Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing Registry.

Trends in preferred place of death among patients with bladder cancer in the United States, 2000 to 2020.

MTHFD1L in muscle invasive bladder cancer: a multi-cohort study on prognosis and therapeutic response.

Serum Biomarkers in Bladder Cancer: NMR Metabolomics for Identification and Monitoring during Platinum-Based Therapy.

Real-World Treatment Sequences and Overall Survival in Metastatic Bladder Cancer: The STATES-Bladder Study - Beyond the Abstract

Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets.

Comorbidity alterations between time for diagnosis and radical cystectomy in patients with muscle invasive bladder cancer undergoing neoadjuvant chemotherapy.

Prospective Multicenter Study of ctDNA Versus Tumor Tissue Guiding FGFR-Targeted Therapy in Metastatic Urothelial Cancer - Beyond the Abstract

Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance.

A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity - Beyond the Abstract

Sarcomatoid urothelial carcinoma with constitutive PD-L1 overexpression.

The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login